Live Breaking News & Updates on Medical expertise provide

Stay informed with the latest breaking news from Medical expertise provide on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Medical expertise provide and stay connected to the pulse of your community

Phathom Pharmaceuticals' (PHAT) "Buy" Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) in a research note released on Friday, Benzinga reports. They currently have a $26.00 price target on the stock. Phathom Pharmaceuticals Stock Up 1.9 % PHAT stock opened at $9.35 on Friday. The stock has a market capitalization […]

Wellington , New-zealand-general- , New-zealand , China , United-states , Canada , Molly-henderson , Terrie-curran , China-universal-asset-management-co , Barclays-plc , Institutional-trading-of-phathom-pharmaceuticals , Insider-activity-at-phathom-pharmaceuticals

Sangamo Therapeutics (NASDAQ:SGMO) Now Covered by StockNews.com

StockNews.com started coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a research note released on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Several other research firms have also issued reports on SGMO. HC Wainwright restated a buy rating and set a $5.00 price target (up previously […]

United-states , Canada , Mackenzie-financial-corp , Sangamo-therapeutics-inc , Royal-bank , Sangamo-therapeutics-company-profile , Miracle-mile-advisors , Sg-americas-securities , Vanguard-personalized-indexing-management , Sangamo-therapeutics , Free-report

Purple Biotech (NASDAQ:PPBT) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Purple Biotech (NASDAQ:PPBT – Free Report) in a research note published on Friday morning, Benzinga reports. They currently have a $10.00 price objective on the stock. Purple Biotech Price Performance Shares of Purple Biotech stock opened at $0.51 on Friday. The firm has a market cap […]

United-states , Armistice-capital , Wuxi-apptec-co , Kingswood-wealth-advisors , Purple-biotech-ltd , Purple-biotech , Free-report , Get-free-report , Wealth-advisors , Wuxi-apptec , Biotech-ltd

Comparing NeueHealth (NYSE:NEUE) and The Cigna Group (NYSE:CI)

The Cigna Group (NYSE:CI – Get Free Report) and NeueHealth (NYSE:NEUE – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, risk and valuation. Analyst Ratings This is a breakdown of current […]

United-states , Connecticut , Florida , Cigna-group-daily , Its-evernorth-health-services , Centrum-health , Cigna-corporation , Neuehealth-inc , Cigna-group , Bright-health-group-inc , Get-free-report

Head to Head Comparison: NeueHealth (NEUE) and Its Competitors

NeueHealth (NYSE:NEUE – Get Free Report) is one of 14 public companies in the “Hospital & medical service plans” industry, but how does it weigh in compared to its competitors? We will compare NeueHealth to similar businesses based on the strength of its earnings, risk, analyst recommendations, dividends, institutional ownership, profitability and valuation. Risk and […]

United-states , Florida , Neuehealth-inc , Centrum-health , Bright-health-group-inc , Get-free-report , Given-neuehealth , Premier-medical-associates , Bright-health-group , Neuehealth-daily , Neuehealth

Encompass Health (NYSE:EHC) Earns Strong-Buy Rating from Raymond James

Raymond James reissued their strong-buy rating on shares of Encompass Health (NYSE:EHC – Free Report) in a research note released on Friday, Benzinga reports. The firm currently has a $95.00 price objective on the stock, up from their previous price objective of $85.00. A number of other equities analysts have also recently issued reports on […]

United-states , Puerto-rico , Canada , Raymond-james , William-blair , Mcglone-suttner-wealth-management-inc , Barclays , Health-company-profile , News-ratings-for-encompass-health-daily , Health-stock-performance , Benjaminf-edwards-company-inc , Health-corporation

Patterson Companies (NASDAQ:PDCO) Given New $27.00 Price Target at Evercore ISI

Patterson Companies (NASDAQ:PDCO – Free Report) had its price objective cut by Evercore ISI from $28.00 to $27.00 in a research report sent to investors on Friday morning, Benzinga reports. They currently have an in-line rating on the stock. Other equities research analysts also recently issued research reports about the stock. SVB Leerink began coverage […]

United-kingdom , Canada , United-states , Piper-sandler , Leerink-partnrs , Analyst-recommendations-for-patterson-companies , Patterson-companies-dividend-announcement , Patterson-companies , Fifth-third-bancorp , Institutional-investors-weigh-in-on-patterson-companies , Patterson-companies-trading , News-ratings-for-patterson-companies-daily

abrdn plc Invests $1.29 Million in G1 Therapeutics, Inc. (NASDAQ:GTHX)

abrdn plc acquired a new stake in G1 Therapeutics, Inc. (NASDAQ:GTHX – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 423,869 shares of the company’s stock, valued at approximately $1,293,000. Several other institutional investors and hedge funds have also recently modified […]

United-states , Rajesh-malik , Needham-company , Acadian-asset-management , Creative-financial-designs-inc , Exchange-commission , Algert-global , Therapeutics-inc , Curi-wealth-management , Nasdaq , Connor-clark-lunn-investment-management-ltd , Free-report

abrdn plc Takes Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

abrdn plc purchased a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 105,073 shares of the company’s stock, valued at approximately $1,499,000. Several other hedge funds and […]

Cambridge , Cambridgeshire , United-kingdom , Japan , Advisor-partners , Takeda-pharmaceutical-company-profile , Cambridge-investment-research-advisors-inc , Takeda-pharmaceutical-company , Sg-americas-securities , Takeda-pharmaceutical-company-limited , Exchange-commission

abrdn plc Purchases New Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

abrdn plc acquired a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 72,032 shares of the company’s stock, valued at approximately $1,459,000. abrdn plc owned approximately 0.22% of Tarsus Pharmaceuticals as of […]

China , United-states , Bobakr-azamian , Aziz-mottiwala , Zurcher-kantonalbank-zurich-cantonalbank , Tarsus-pharmaceuticals-inc , Tarsus-pharmaceuticals-company-profile , Securities-exchange-commission , Mirae-asset-global-investments-co , Tarsus-pharmaceuticals-stock , Quarter-for-tarsus-pharmaceuticals , News-ratings-for-tarsus-pharmaceuticals-daily